23andMe Holding Co. has signed a definitive agreement to sell nearly all of its assets to TTAM Research Institute for $305 million.
The assets involved include the Personal Genome Service (PGS), Research Services business lines, and Lemonaid Health.
This deal comes after a final bidding round between TTAM and Regeneron Pharmaceuticals.
Upon court approval, the agreement with TTAM will replace and void the prior acquisition agreement with Regeneron valued at $256 million.
The court hearing for approval is scheduled for June 17, 2025.
The transaction is expected to close in the coming weeks.
